Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Synnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of Directors

Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial with a First-in-Class T-Cell Engager Designed to Target Cancer Cells with Absolute Specificity